[go: up one dir, main page]

MA32556B1 - Composition pharmaceutique - Google Patents

Composition pharmaceutique

Info

Publication number
MA32556B1
MA32556B1 MA33607A MA33607A MA32556B1 MA 32556 B1 MA32556 B1 MA 32556B1 MA 33607 A MA33607 A MA 33607A MA 33607 A MA33607 A MA 33607A MA 32556 B1 MA32556 B1 MA 32556B1
Authority
MA
Morocco
Prior art keywords
active ingredient
pharmaceutically active
pharmaceutical composition
stabilized
preparation containing
Prior art date
Application number
MA33607A
Other languages
Arabic (ar)
English (en)
Inventor
Yasuhiro Hiraishi
Muneo Nonomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32556(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32556B1 publication Critical patent/MA32556B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique ou une préparation solide contenant un principe pharmaceutiquement actif stabilisé et un procédé de stabilisation de celle-ci. Selon la présente invention, une composition peut être pharmaceutiquement stabilisée par un contenu de principe pharmaceutiquement actif non peptidique possédant un groupe amino primaire ou secondaire, un excipient et un composé acide. Par ailleurs, une préparation solide contenant un principe pharmaceutiquement actif, un oxyde de titane, un plastifiant et un acide organique à chaîne peut renforcer la stabilité du principe pharmaceutiquement actif pendant une irradiation lumineuse.
MA33607A 2008-07-28 2011-02-11 Composition pharmaceutique MA32556B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28
PCT/JP2009/063708 WO2010013823A2 (fr) 2008-07-28 2009-07-27 Composition pharmaceutique

Publications (1)

Publication Number Publication Date
MA32556B1 true MA32556B1 (fr) 2011-08-01

Family

ID=41327301

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33607A MA32556B1 (fr) 2008-07-28 2011-02-11 Composition pharmaceutique

Country Status (29)

Country Link
US (2) US9186411B2 (fr)
EP (2) EP2309985B1 (fr)
JP (2) JP5295356B2 (fr)
KR (1) KR20110042334A (fr)
CN (3) CN102164581A (fr)
AR (1) AR072842A1 (fr)
AU (1) AU2009277443A1 (fr)
BR (1) BRPI0916689A2 (fr)
CA (2) CA2936400C (fr)
CL (1) CL2011000170A1 (fr)
CO (1) CO6290638A2 (fr)
CR (1) CR20110110A (fr)
DO (2) DOP2011000033A (fr)
EA (2) EA201170272A1 (fr)
EC (1) ECSP11010855A (fr)
ES (2) ES2669592T3 (fr)
GE (2) GEP20146166B (fr)
IL (2) IL210735A0 (fr)
MA (1) MA32556B1 (fr)
MX (1) MX2011000757A (fr)
MY (2) MY156305A (fr)
NZ (2) NZ591344A (fr)
PE (3) PE20140977A1 (fr)
SG (1) SG186685A1 (fr)
TW (2) TW201010992A (fr)
UA (1) UA103332C2 (fr)
UY (1) UY32008A (fr)
WO (1) WO2010013823A2 (fr)
ZA (1) ZA201101198B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150011549A1 (en) * 2012-02-15 2015-01-08 Takeda Pharmaceutical Company Limited Tablet
CA2877619C (fr) * 2012-06-27 2020-09-22 Takeda Pharmaceutical Company Limited Preparations liquides d'amines et d'acides organiques stabilises par des sels
KR101609105B1 (ko) * 2012-09-19 2016-04-04 다이호야쿠힌고교 가부시키가이샤 용출성 및/또는 흡수성이 개선된 경구 투여용 의약 조성물
EP2968695A1 (fr) * 2013-03-14 2016-01-20 Allergan, Inc. Système en polymère pour fixer des implants dans des aiguilles de seringue
CN105330647A (zh) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
MX386414B (es) 2015-07-30 2025-03-18 Takeda Pharmaceuticals Co Tableta.
CN105106203B (zh) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 富马酸沃诺拉赞的药物组合物及其制备方法
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
WO2018071233A1 (fr) * 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Dispersions solides amorphes
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN106860852A (zh) * 2017-02-17 2017-06-20 王清华 一种用于结合治疗胃病的粘液西药
JP2020521795A (ja) 2017-05-31 2020-07-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング （Ｅ）−４−（２−（アミノメチル）−３−フルオロアリルオキシ）−Ｎ−ｔｅｒｔ−ブチルベンズアミドを含む医薬組成物および医薬剤形、それらの調製方法、治療方法およびそれらの使用
WO2019013310A1 (fr) 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited Préparation comprenant du vonoprazan
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN109288722B (zh) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 一种变色修正肤色的粉底及其制备方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
RS64501B1 (sr) * 2020-04-24 2023-09-29 Dr Falk Pharma Gmbh Sistemska formulacija derivata piridinona za celijačnu bolest
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN114053239A (zh) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 一种富马酸伏诺拉生药物组合物及制备方法
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
WO2022072811A1 (fr) * 2020-10-01 2022-04-07 Imago Biosciences, Inc. Formulations pharmaceutiques pour le traitement de maladies médiées par kdm1a
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
CN115364065B (zh) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 富马酸伏诺拉生片
CN115944743B (zh) * 2023-01-18 2025-08-08 山东诚成医药科技有限公司 一种富马酸伏诺拉生组合物及其制备方法
WO2025064381A1 (fr) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Procédé de préparation de vonoprazan à teneur en nitrosamine réduite
CN119970680B (zh) * 2023-11-10 2025-10-03 中国人民解放军军事科学院军事医学研究院 一种秋水仙碱缓释微丸及其制备方法
CN117462507B (zh) * 2023-12-28 2024-03-15 山东齐都药业有限公司 富马酸伏诺拉生药物组合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (fr) 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
ATE241341T1 (de) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
JP4730985B2 (ja) 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CA2404226A1 (fr) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derives de furoisoquinoleine, leur procede de production et leur utilisation
EP1419775A1 (fr) * 2001-07-30 2004-05-19 Mitsubishi Pharma Corporation Preparations pharmaceutiques stables contenant comme principe actif des derives de l'acide aminobenzenesulphonique
JP4394443B2 (ja) 2001-10-17 2010-01-06 久光製薬株式会社 経皮吸収型製剤
US7247702B2 (en) * 2002-02-28 2007-07-24 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
BRPI0306559B8 (pt) 2002-03-07 2021-05-25 Boehringer Ingelheim Int composição farmacêutica para aplicação oral para mesilato de etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2-il-amino]-propiônico e seu processo de preparação
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (de) * 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
WO2004056337A2 (fr) * 2002-12-18 2004-07-08 Pain Therapeutics Formes posologiques orales comprenant des agents actifs au plan therapeutique dans des noyaux a liberation lente et des revetements de capsule en gelatine a liberation immediate
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
AR045062A1 (es) 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP2005263788A (ja) * 2004-02-17 2005-09-29 Sankyo Co Ltd インドリン化合物を含有する安定化された医薬組成物
KR20120064735A (ko) * 2004-04-01 2012-06-19 아지노모토 가부시키가이샤 나테글리니드 함유 제제
JP2006001912A (ja) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd タンパク質製剤の安定化方法
EP2336107B1 (fr) * 2004-09-30 2015-09-23 Takeda Pharmaceutical Company Limited Inhibiteurs de pompe a protons
AU2005291302A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
WO2007023931A1 (fr) * 2005-08-25 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. Préparation pour la prévention de l'augmentation de la concentration sanguine en alcool
PE20110009A1 (es) * 2005-08-30 2011-01-31 Takeda Pharmaceutical Derivados de pirrol como inhibidores de la secrecion acida
EP1967184A4 (fr) 2005-12-28 2011-02-16 Takeda Pharmaceutical Preparation solide a liberation controlee
CA2662938A1 (fr) * 2006-09-15 2008-03-20 Astellas Pharma Inc. Composition pharmaceutique solide pour administration orale comprenant du ramosetron optiquement stable
JP5074052B2 (ja) 2007-02-13 2012-11-14 有限会社愛和ライト 遊技機
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
TW200920366A (en) 2007-09-28 2009-05-16 Takeda Pharmaceutical 5-membered heterocyclic compound
JP5379690B2 (ja) 2007-09-28 2013-12-25 武田薬品工業株式会社 ５員複素環化合物
EP2226075A1 (fr) 2007-11-22 2010-09-08 The University of Tokyo Matériau destiné à la prévention de l'adhérence tissulaire et matériau destiné à la prévention des contractures articulaires

Also Published As

Publication number Publication date
JP2011529445A (ja) 2011-12-08
US20130261156A1 (en) 2013-10-03
ZA201101198B (en) 2012-05-30
CA2732243C (fr) 2016-11-29
EA201201451A1 (ru) 2013-07-30
SG186685A1 (en) 2013-01-30
TW201010992A (en) 2010-03-16
GEP20146122B (en) 2014-07-25
IL228817A0 (en) 2013-12-31
NZ602592A (en) 2014-01-31
CL2011000170A1 (es) 2011-06-10
CA2936400C (fr) 2018-03-27
EP2309985B1 (fr) 2018-03-14
JP2013047239A (ja) 2013-03-07
GEP20146166B (en) 2014-09-25
EP2564833B1 (fr) 2017-12-20
CA2732243A1 (fr) 2010-02-04
WO2010013823A2 (fr) 2010-02-04
UA103332C2 (ru) 2013-10-10
AU2009277443A1 (en) 2010-02-04
CN102743330B (zh) 2016-03-23
NZ591344A (en) 2013-03-28
KR20110042334A (ko) 2011-04-26
PE20141585A1 (es) 2014-11-13
MY156305A (en) 2016-01-29
PE20110591A1 (es) 2011-09-15
DOP2011000033A (es) 2011-04-15
CN102743330A (zh) 2012-10-24
DOP2013000172A (es) 2013-11-15
EA201170272A1 (ru) 2011-10-31
PE20140977A1 (es) 2014-08-20
JP5593363B2 (ja) 2014-09-24
MY169461A (en) 2019-04-11
ES2660962T3 (es) 2018-03-26
EP2309985A2 (fr) 2011-04-20
CN102164581A (zh) 2011-08-24
BRPI0916689A2 (pt) 2015-11-17
CA2936400A1 (fr) 2010-02-04
CO6290638A2 (es) 2011-06-20
EP2564833A1 (fr) 2013-03-06
TW201431552A (zh) 2014-08-16
US20110124687A1 (en) 2011-05-26
JP5295356B2 (ja) 2013-09-18
ES2669592T3 (es) 2018-05-28
MX2011000757A (es) 2011-02-24
IL210735A0 (en) 2011-03-31
CR20110110A (es) 2011-04-28
UY32008A (es) 2010-02-26
AR072842A1 (es) 2010-09-22
WO2010013823A3 (fr) 2010-04-15
US9186411B2 (en) 2015-11-17
ECSP11010855A (es) 2011-03-31
CN104784180A (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
MA32556B1 (fr) Composition pharmaceutique
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
EA201391758A1 (ru) Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
WO2008021871A3 (fr) Inhibiteurs triazolyle acyclique de la sérine protéase de l'hépatite c
WO2008019266A3 (fr) Inhibiteurs de sérine protéase de l'hépatite c dérivés de pyridazinone acycliques
ECSP045307A (es) Combinacion de compuestos organicos
MA31706B1 (fr) Formulations galéniques de composés organiques
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PH12023552774A1 (en) Nek7 inhibitors
WO2007022255A3 (fr) Preparations pharmaceutiques a liberation prolongee
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
BR112022015925A2 (pt) Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos
PL1853292T3 (pl) Kompozycja farmaceutyczna, zawierająca związki glutationu i betalainy, do prewencji i do zwalczania raka
PE20220486A1 (es) Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
EA201170338A1 (ru) Способ и состав для лечения неблагоприятных биологических состояний
MX378113B (es) Composiciones para la prevención y el tratamiento profiláctico de dermatitis por hiedra venenosa.
WO2008057464A3 (fr) Compositions et procédés servant à améliorer la biodisponibilité de la liothyronine
MA29560B1 (fr) Formulation a liberation prolongee de principes actifs de medicaments
WO2010056041A3 (fr) Composition pharmaceutique destinée au traitement et à la prévention d'affections cardiaques résultant d'ischémie ou de reperfusion ischémique
BRPI0507030A (pt) combinação de compostos orgánicos
FR3117337B1 (fr) Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
TN2011000030A1 (en) Pharaceutical composition
WO2007047881A3 (fr) Methode de traitement de la douleur
EP2638902B1 (fr) Médicament antipaludique comprenant de l'alaremycine ou un dérivé de celle-ci comme principe actif
UY40494A (es) Potenciadores novedosos de los canales de potasio sensibles a atp, su preparación y uso